Low Bleeding Risk Associated With Use of Clopidogrel During Polypectomy

Researchers at the Dallas Veterans Administration Medical Center found that the use of clopidogrel during polypectomy has a 0.9 percent risk for bleeding in patients who already have a risk for bleeding, according to a news report. Researchers said this “acceptably low” rate does not warrant stopping the medication before the procedure.

Lead investigator Linda Anne Feagins, MD, assistant professor in the Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, and clinician at the Dallas Veterans Administration Medical Center, said the risk of discontinuing the drug exceeds the risk of bleeding. About 6 percent of stent thromboses in patients who discontinued clopidogrel occurred within 10 days.

Current ASGE guidelines recommend clinicians consider discontinuing clopidogrel seven to 10 days before elective polypectomy in patients who are at high risk for bleeding.

Next Up in GI & Endoscopy

Low Bleeding Risk Associated With Use of Clopidogrel During Polypectomy

Next Up in GI & Endoscopy

FDA clears final trial stage for robotic GI surgery system

Gastroenterologist pay breakdown in 10 stats

5 GI leaders on what’s changing in colonoscopy

Shadow AI: How 5 systems are managing risk + empowering responsible innovation

Next Up in GI & Endoscopy

FDA clears final trial stage for robotic GI surgery system

Gastroenterologist pay breakdown in 10 stats

5 GI leaders on what’s changing in colonoscopy

Join the 40,000+ ASC leaders who start their day with Becker's